Neos Theraps Inc patents expiration
1. Adzenys Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8709491 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(8 years from now) | |
| US9017731 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(8 years from now) | |
| US9265737 | NEOS THERAPS INC | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
Drugs and Companies using AMPHETAMINE ingredient
Market Authorisation Date: 15 September, 2017
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
More Information on Dosage
ADZENYS ER family patents
2. Cotempla Xr-odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8840924 | NEOS THERAPS INC | Compositions and methods of making rapidly dissolving ionically masked formulations |
Jun, 2026
(2 years from now) | |
| US9089496 | NEOS THERAPS INC | Compositions comprising methylphenidate complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
| US9072680 | NEOS THERAPS INC | Compositions comprising methylphenidate complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
| US11166947 | NEOS THERAPS INC | Effective dosing of a child for the treatment of ADHD with methylphenidate |
Jan, 2038
(14 years from now) | |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
How can I launch a generic of COTEMPLA XR-ODT before it's drug patent expiration?
More Information on Dosage
COTEMPLA XR-ODT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic